ACELRX PHARMACEUTICALS INC (ACRX)       2.39  0 (0%)

2.39  0 (0%)

US00444T2096 - Common Stock

ACELRX PHARMACEUTICALS INC2.39

NASDAQ:ACRX (12/1/2022, 9:49:46 AM)0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/amc Earnings (Next) 03-08 2023-03-08
Ins Owners 39.59% Inst Owners 244.6%
Market Cap 17.80M Shares 7.45M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 80
IPO 02-11 2011-02-11

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACRX Daily chart

Company Profile

AcelRx Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Hayward, California and currently employs 43 full-time employees. The company went IPO on 2011-02-11. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.

Company Info

ACELRX PHARMACEUTICALS INC

25821 Industrial Boulevard, Suite 400

Hayward CALIFORNIA 94063

P: 16502163500.0

CEO: Vincent J. Angotti

Employees: 43

Website: http://www.acelrx.com

ACRX News

News Image17 days ago - BusinessInsiderAcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M i...

News Image17 days ago - AcelRx Pharmaceuticals, Inc.AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

News Imagea month ago - AcelRx Pharmaceuticals, Inc.AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter...

News Imagea month ago - AcelRx Pharmaceuticals, Inc.AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

News Imagea month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to start off the day with a breakdown of the biggest pre-market stock movers for Wednesday morning and the latest news!

News Imagea month ago - AcelRx Pharmaceuticals, Inc.AcelRx Pharmaceuticals Announces Reverse Stock Split

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...

ACRX Twits

Here you can normally see the latest stock twits on ACRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example